|
SLC38A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.57309745627299E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.45150052772203E-10 |
| Normal-vs-Stage2 |
7.16259999977709E-07 |
| Normal-vs-Stage3 |
1.83759999994315E-07 |
| Normal-vs-Stage4 |
2.84600000233226E-08 |
| Stage1-vs-Stage2 |
4.330200E-01 |
| Stage1-vs-Stage3 |
3.194000E-01 |
| Stage1-vs-Stage4 |
1.183990E-01 |
| Stage2-vs-Stage3 |
9.369800E-01 |
| Stage2-vs-Stage4 |
5.600400E-01 |
| Stage3-vs-Stage4 |
5.929800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.44269995949742E-09 |
| Normal-vs-AfricanAmerican |
8.24430002044352E-09 |
| Normal-vs-Asian |
5.93689999999203E-05 |
| Caucasian-vs-AfricanAmerican |
6.791700E-02 |
| Caucasian-vs-Asian |
4.900400E-01 |
| AfricanAmerican-vs-Asian |
4.681800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.45499986795528E-10 |
| Normal-vs-Female |
5.44720046846692E-10 |
| Male-vs-Female |
3.411800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.378700002583E-08 |
| Normal-vs-Age(41-60Yrs) |
1.67110769666579E-12 |
| Normal-vs-Age(61-80Yrs) |
5.65359999926685E-08 |
| Normal-vs-Age(81-100Yrs) |
1.302240E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.908400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.352970E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.893400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.326200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.877400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.555200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.033800E-01 |
| Classical-VS-Follicular |
2.101600E-02 |
| Classical-VS-Other |
6.014200E-01 |
| Classical-VS-Normal |
5.86170001426467E-10 |
| Tall-VS-Follicular |
3.395000E-01 |
| Tall-VS-Other |
7.293400E-01 |
| Tall-VS-Normal |
1.176500E-02 |
| Follicular-VS-Other |
8.131400E-01 |
| Follicular-VS-Normal |
1.02550001823687E-09 |
| Other-VS-Normal |
1.177910E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2374545832472E-12 |
| Normal-vs-N1 |
1.69925999999876E-05 |
| N0-vs-N1 |
1.770780E-01 |
|
|
